Abstract
Thyroid-associated ophthalmopathy (TAO) is now the most prevalent orbital disease in adults, with a complex pathophysiology and a wide range of clinical symptoms. In recent years, significant progress has been made in the research on the treatment of TAO. Periorbital steroid injections are considered a precise local treatment and can improve ocular symptoms with minor side effects. However, there is no standardized orbital injection protocol in China, resulting in increased complications. Therefore, it is essential to standardize periorbital steroid injections in treating TAO.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: [Zhonghua yan ke za zhi] Chinese journal of ophthalmology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
